Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Pharmaceuticals5.46%+0.97 ppManaged Health Care2.54%+0.50 ppBiotechnology2.50%+0.42 ppLife Sciences Tools & Services2.04%+0.09 ppHealth Care Supplies0.18%-0.09 ppHealth Care Distributors0.38%+0.08 ppHealth Care Equipment3.17%-0.07 ppHealth Care Services0.91%+0.04 ppHealth Care Facilities0.24%-0.01 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.50%
Industry change · 12M
+0.42 pp
Biotechnology · contribution
+0.416 pp
Company participation
63%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Apr 2022 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| AbbVie → ABBV | United States | $259.8bn | 0.939% | +0.125 pp | +0.226 pp | +37.4% | Yes |
| Moderna → MRNA | United States | $54.2bn | 0.196% | -0.035 pp | +0.196 pp | -24.8% | No |
| Regeneron Pharmaceuticals → REGN | United States | $61.9bn | 0.224% | +0.032 pp | +0.060 pp | +36.9% | Yes |
| Amgen → AMGN | United States | $124.6bn | 0.450% | +0.020 pp | -0.049 pp | +0.4% | Yes |
| Vertex Pharmaceuticals → VRTX | United States | $69.6bn | 0.251% | +0.044 pp | +0.047 pp | +25.2% | Yes |
| Biogen → BIIB | United States | $30.5bn | 0.110% | -0.001 pp | -0.036 pp | -22.4% | No |
| Gilead Sciences → GILD | United States | $74.4bn | 0.269% | -0.021 pp | -0.020 pp | -2.4% | No |
| Incyte → INCY | United States | $16.6bn | 0.060% | +0.005 pp | -0.008 pp | -12.2% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.